Imipenem/cilastatin as initial single-agent therapy for infections in cancer patients with neutropenia.
Fassas
A
A
Dept. of Hematology and Dept. of Microbiology, George Papanicolaou General Hospital, Thessaloniki, Greece.
Papageorgiou
T
T
Kontodimou
A
A
Proya
E
E
Hadjikyrkou
M
M
Anagnostopoulos
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000097:blood; D001424:Bacterial Infections / Q000097:blood* / Q000188:drug therapy; D015377:Cilastatin / Q000627:therapeutic use; D000077728:Cilastatin, Imipenem Drug Combination; D004338:Drug Combinations; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009369:Neoplasms / Q000382:microbiology*; D009503:Neutropenia / Q000209:etiology*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D015377:Cilastatin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination